07
Jun
US biotech outperforms again
After outperforming the S&P500 in 2020 and matching the Nasdaq, the Biotechnology sector experienced a long dry spell in 2021 and 2022. The S&P Biotechnology index's collapse of almost -41% in two years proved bloodier than the Nasdaq's -13.8% fall, and even more so in the face of the S&P500's +5% advance. Too many companies, (...)
To make sure you don’t miss any of our publications and have access to exclusive research, don’t hesitate to click on the button below to join our Newsletter!
